Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isosorbide Mononitrate for Anti-VEGF Induced Kidney Injury
NCT04051957Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney injury (AKI), proteinuria and hypertension (HTN) comparing Isosorbide Mononitrate Arm with Placebo Arm (2 arms). Primary endpoint: Reduction in Urine Protein Creatinine Ratio at 3 months. Started Sep 2019; status: terminated.
02
Drugs
isosorbide mononitrate
03
Conditions
acute kidney injury (AKI)proteinuriahypertension (HTN)
Beyond the preview
Go deeper on NCT04051957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051957.